C

Can-Fite BioPharma Ltd
D

CANF

1.78000
USD
-0.06
(-3.26%)
Market Closed
Volume
7,926
EPS
-0
Div Yield
-
P/E
-1
Market Cap
10,851,642
Related Instruments
    A
    AEMD
    -0.01550
    (-2.58%)
    0.58640 USD
    A
    APDN
    -0.00530
    (-3.25%)
    0.15790 USD
    A
    AXON
    -28.72
    (-5.30%)
    513.31 USD
    M
    MESA
    -0.06500
    (-5.31%)
    1.16000 USD
    O
    OCUL
    -0.26000
    (-3.58%)
    6.99500 USD
    More
News

Title: Can/Fite BioPharma Ltd

Sector: Healthcare
Industry: Biotechnology
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed intoa Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.